open access

Vol 21, No 6 (2016)
Original research articles
Published online: 2016-11-01
Submitted: 2016-06-09
Get Citation

Low dose palliative radiotherapy for refractory aggressive lymphoma

Osamu Tanaka, Masahiko Oguchi, Takayoshi Iida, Senji Kasahara, Hideko Goto, Takeshi Takahashi
DOI: 10.1016/j.rpor.2016.07.009
·
Rep Pract Oncol Radiother 2016;21(6):495-499.

open access

Vol 21, No 6 (2016)
Original research articles
Published online: 2016-11-01
Submitted: 2016-06-09

Abstract

Aim

To determine the efficacy of low-dose palliative radiotherapy in patients with refractory aggressive lymphoma.

Background

There are few reports on the administration of palliative radiotherapy to patients with aggressive lymphoma.

Materials and methods

The present study included 11 patients with 30 sites of aggressive lymphoma (diffuse large cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]7; mantle cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]2; follicular large cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1; and peripheral T cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1). The patients received local palliative radiotherapy after receiving a median of 4 chemotherapy regimens. The radiotherapy doses administered to the 30 sites were as follows: 8[[ce:hsp sp="0.25"/]]Gy, single fraction (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]27); 6[[ce:hsp sp="0.25"/]]Gy, single fraction (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1); 4[[ce:hsp sp="0.25"/]]Gy, single fraction (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1); and 4[[ce:hsp sp="0.25"/]]Gy, 2 fractions (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1).

Results

The complete response rate was 45% (5/11); the partial response rate was 36% (4/11). Toxicity occurred at one irradiated site (the mandibular), which showed temporal acute gingivitis; however, medication was not required. Retreatment was required for 3 sites on the head (parotid, face and mandible) due to persistent discomfort. None of the other sites (27/30) required retreatment. A patient with refractory DLBCL underwent radiotherapy (4[[ce:hsp sp="0.25"/]]Gy, single fraction) for hepatic hilar lymph node involvement but did not recover from jaundice and died of DLBCL.

Conclusions

Eight Gray single fraction radiotherapy was one of meaningful options for the treatment of refractory aggressive lymphoma in terms of its efficacy and the incidence of adverse events. The use of 8[[ce:hsp sp="0.25"/]]Gy single fraction radiotherapy is therefore recommended for achieving local control in patients with refractory aggressive lymphoma.

Abstract

Aim

To determine the efficacy of low-dose palliative radiotherapy in patients with refractory aggressive lymphoma.

Background

There are few reports on the administration of palliative radiotherapy to patients with aggressive lymphoma.

Materials and methods

The present study included 11 patients with 30 sites of aggressive lymphoma (diffuse large cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]7; mantle cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]2; follicular large cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1; and peripheral T cell lymphoma, n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1). The patients received local palliative radiotherapy after receiving a median of 4 chemotherapy regimens. The radiotherapy doses administered to the 30 sites were as follows: 8[[ce:hsp sp="0.25"/]]Gy, single fraction (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]27); 6[[ce:hsp sp="0.25"/]]Gy, single fraction (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1); 4[[ce:hsp sp="0.25"/]]Gy, single fraction (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1); and 4[[ce:hsp sp="0.25"/]]Gy, 2 fractions (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1).

Results

The complete response rate was 45% (5/11); the partial response rate was 36% (4/11). Toxicity occurred at one irradiated site (the mandibular), which showed temporal acute gingivitis; however, medication was not required. Retreatment was required for 3 sites on the head (parotid, face and mandible) due to persistent discomfort. None of the other sites (27/30) required retreatment. A patient with refractory DLBCL underwent radiotherapy (4[[ce:hsp sp="0.25"/]]Gy, single fraction) for hepatic hilar lymph node involvement but did not recover from jaundice and died of DLBCL.

Conclusions

Eight Gray single fraction radiotherapy was one of meaningful options for the treatment of refractory aggressive lymphoma in terms of its efficacy and the incidence of adverse events. The use of 8[[ce:hsp sp="0.25"/]]Gy single fraction radiotherapy is therefore recommended for achieving local control in patients with refractory aggressive lymphoma.

Get Citation

Keywords

Low dose radiotherapy; Palliation; Salvage; Refractory lymphoma; Quality of life

About this article
Title

Low dose palliative radiotherapy for refractory aggressive lymphoma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 21, No 6 (2016)

Pages

495-499

Published online

2016-11-01

DOI

10.1016/j.rpor.2016.07.009

Bibliographic record

Rep Pract Oncol Radiother 2016;21(6):495-499.

Keywords

Low dose radiotherapy
Palliation
Salvage
Refractory lymphoma
Quality of life

Authors

Osamu Tanaka
Masahiko Oguchi
Takayoshi Iida
Senji Kasahara
Hideko Goto
Takeshi Takahashi

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl